PCSK9 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00483 Copy Product Info

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

PCSK9 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00483

Copy Product Info

PCSK9 Protein, Cynomolgus, Recombinant (His)

Pack Size	Price	USA Stock	Global Stock
5 μg	$51	7-10 days	7-10 days
10 μg	$80	7-10 days	7-10 days
20 μg	$129	7-10 days	7-10 days
50 μg	$248	7-10 days	7-10 days
100 μg	$418	7-10 days	7-10 days
200 μg	$757	7-10 days	7-10 days
500 μg	$1,670	7-10 days	7-10 days

Add to Cart

Add to Quotation

In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	1. Immobilized Cynomolgus PCSK9, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve Anti-PCSK9 Antibody, hFc Tag with the EC50 of 81.5ng/ml determined by ELISA (QC Test). 2. Cynomolgus LDLR, His Tag immobilized on CM5 Chip can bind Cynomolgus PCSK9, His Tag with an affinity constant of 0.27 nM as determined in SPR assay.
Description	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Species	Cynomolgus
Expression System	HEK293 Cells
Tag	C-His
Accession Number	A0A2K5TZC4
Synonyms	PCSK9
Construction	Glu151-Gln811
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.